Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin lymphoma (HL)

被引：0
|
作者：
Younes, A. [5 ]
Kuruvilla, J. [4 ]
Pro, B. [5 ]
Wedgwood, A. [5 ]
Li, Z. [3 ]
Drouin, M. [3 ]
Patterson, T. [3 ]
Ward, R. [2 ]
Martell, R. E. [3 ]
Bociek, R. G. [1 ]
机构：
[1] Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE USA
[2] Pharm Corp, Clin Operat, Boulder, CO USA
[3] Drug Dev MethylGene Inc, Montreal, PQ, Canada
[4] Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON M4X 1K9, Canada
[5] Univ Texas Houston, MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：128 / 128
页数：1
相关论文
共 50 条
  • [31] Phase II study of MGCD0103 in patients with relapsed follicular lymphoma (FL): Study reinitiation and update of clinical efficacy and safety.
    Martell, R. E.
    Younes, A.
    Assouline, S. E.
    Rizzieri, D.
    Fox, S.
    Drouin, M. A.
    Wilhelm, J.
    Mehran, M.
    Besterman, J. M.
    Van der Jagt, R. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [32] Resminostat In Relapsed or Refractory Hodgkin Lymphoma: Initial Results of the SAPHIRE Phase II Trial with a Novel Oral Histone Deacetylase (HDAC) Inhibitor
    Walewski, Jan
    Paszkiewicz-Kozik, Ewa
    Borsaru, Gabriela
    Moicean, Andreea
    Warszewska, Agnieszka
    Strobel, Klaus
    Biggi, Alberto
    Hauns, Bernhard
    Mais, Anna
    Henning, Stefan W.
    Hentsch, Bernd
    BLOOD, 2010, 116 (21) : 1159 - 1159
  • [33] A phase II study of mocetinostat, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in combination with 5-azacitidine in patients with myelodysplastic syndrome (MDS)
    Luger, Selina M.
    O'Connell, Casey Lee
    Klimek, Virginia
    Cooper, Maureen A.
    Besa, Emmanuel C.
    Rossetti, James M.
    Reid, Gregory K.
    Humphrey, Rachel
    Martell, Robert E.
    Garcia-Manero, Guillermo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [34] INITIAL RESULTS FROM THE SAPHIRE STUDY: A PHASE II TRIAL WITH THE NOVEL ORAL HISTONE DEACETYLASE (HDAC) INHIBITOR RESMINOSTAT IN RELAPSED OR REFRACTORY HODGKIN'S LYMPHOMA PATIENTS
    Walewski, J.
    Paszkiewicz-Kozik, E.
    Borsaru, G.
    Moicean, A.
    Warszewska, A.
    Strobel, K.
    Biggi, A.
    Hauns, B.
    Mais, A.
    Henning, S.
    Hentsch, B.
    HAEMATOLOGICA, 2010, 95 : S27 - S27
  • [35] Phase II study of the histone-deacetylase inhibitor ITF2357 in relapsed/refractory Hodgkin's lymphoma patients
    Viviani, S.
    Bonfante, V.
    Fasola, C.
    Valagussa, P.
    Gianni, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] Oral histone deacetylase inhibitor HBI-8000 (tucidinostat) in Japanese patients with relapsed or refractory non-Hodgkin's lymphoma: phase I safety and efficacy
    Yoshimitsu, Makoto
    Ando, Kiyoshi
    Ishida, Takashi
    Yoshida, Shinichiro
    Choi, Ilseung
    Hidaka, Michihiro
    Takamatsu, Yasushi
    Gillings, Mireille
    Lee, Gloria T.
    Onogi, Hiroshi
    Tobinai, Kensei
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (09) : 1014 - 1020
  • [37] A phase II study of single agent mocetinostat, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in patients with diffuse large cell B-cell (DLBCL) and follicular (FL) lymphomas
    Crump, Michael
    Andreadis, Charalambos
    Assouline, Sarit E.
    Rizzieri, David
    Copeland, Amanda
    Van Der Jagt, Richard H. C.
    Fox, Susan
    Reid, Gregory K.
    Besterman, Jeffrey M.
    Martell, Robert E.
    Younes, Anas
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [38] ABEXINOSTAT (S78454) A HISTONE DEACETYLASE INHIBITOR, IN PATIENTS WITH REFRACTORY OR RELAPSED HODGKIN'S LYMPHOMA, NON-HODGKIN LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKAEMIA: PRELIMINARY PHASE II RESULTS
    Broussais-Guillaumot, F.
    Morschhauser, F.
    Terriou, L.
    Kim, W. S.
    Lim, S. T.
    Egyed, M.
    Coiffier, B.
    Bachy, E.
    Dyer, M. J.
    Illes, A.
    Rosta, A.
    Lemieux, B.
    Wu, K. L.
    Yoon, S. S.
    Kim, S.
    Gasztonyi, Z.
    Jakucs, J.
    Offner, F.
    Van den Neste, E.
    Ysebaert, L.
    Wendtner, C. M.
    Kloos, I.
    Sarry, A. L.
    Malasse, S.
    Ribrag, V.
    HAEMATOLOGICA, 2014, 99 : 141 - 142
  • [39] Phase I clinical trial of oral administration of the histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with relapsed/refractory multiple myeloma
    Richardson, P
    Schlossman, RL
    Mitsiades, CS
    Munshi, NC
    Colson, K
    Doss, D
    McKenney, M
    Hande, K
    Gorelik, S
    Lunde, L
    Stepanek, A
    Freeman, A
    Dinand, K
    Hayes, S
    Michelle, R
    Doucet, K
    Warren, D
    Mitsiades, N
    Richon, VM
    Chiao, J
    Anderson, KC
    BLOOD, 2004, 104 (11) : 420A - 420A
  • [40] The Oral Selective Inhibitor of Nuclear Export ( SINE) Selinexor (KPT-330) Demonstrates Broad and Durable Clinical Activity in Relapsed / Refractory Non Hodgkin's Lymphoma (NHL)
    Kuruvilla, John
    Byrd, John C.
    Flynn, Joseph M.
    Garzon, Ramiro
    Porcu, Pierluigi
    Wagner-Johnston, Nina
    Savoie, Mary Lynn
    Stone, Richard M.
    Jacobsen, Eric D.
    Mau-Sorensen, Morten
    Brown, Peter de Nully
    Baz, Rachid
    Shal, Bijal
    Flinn, Ian
    Gabrail, Nashat
    Kukreti, Vishal
    Tiedemann, Rodger E.
    Landesman, Yosef
    Klebanov, Boris
    Shacham, Eran
    Saint-Martin, Jean-Richard
    Marshall, Tracey
    McCartney, John
    McCauley, Dilara
    Carlson, Robert
    Norori, Sasha
    Savona, Michael R.
    Rashal, Tami
    Mirza, Mansoor R.
    Kauffman, Michael
    Shacham, Sharon
    BLOOD, 2014, 124 (21)
12345